Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups

BACKGROUND: The advent of immuno-oncology (IO) represented a breakthrough in non-small cell lung cancer (NSCLC) therapy over the last few years. However, establishing the optimal therapeutic options among programmed death-ligand 1 (PD-L1) selected subgroups still addresses an unmet need in the clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Passiglia, Francesco, Galvano, Antonio, Gristina, Valerio, Barraco, Nadia, Castiglia, Marta, Perez, Alessandro, La Mantia, Maria, Russo, Antonio, Bazan, Viviana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350096/
https://www.ncbi.nlm.nih.gov/pubmed/34430351
http://dx.doi.org/10.21037/tlcr-21-52

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350096/
https://www.ncbi.nlm.nih.gov/pubmed/34430351
http://dx.doi.org/10.21037/tlcr-21-52

Ejemplares similares